MCM. S. Cherepianskii

M. S. Cherepianskii

*This is an algorithmically generated author record based on publicly available information.

M. S. Cherepianskii has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Siponimod in acute ischemic stroke: rationale for the selective sphingosine-1-phosphate receptor modulator repurposing hypothesis with a focus on cardiovascular safety. A review

    by M. S. Cherepyansky, O. N. Kurochkina, A. V. Baranov

    Acute ischemic stroke remains a cause of high mortality and disability. Existing treatments are limited by a small therapeutic window. Fingolimod has demonstrated neuroprotective potential, but its use is limited by cardiovascular risks (bradycardia) due to S1PR3 activation. Siponimod is a selective S1PR1/S1PR5 modulator without activity on S1PR3. Analysis of the mechanisms of action, clinical data, and pharmacoeconomic modeling indicate that siponimod may be more effective and safer than fingolimod in ischemic stroke. Artificial intelligence modeling of a clinical trial shows that the use of siponimod in 1000 patients could prevent disability in 510 people and save over RUB1,6 billion. The ICER is 11765 RUB/QALY. Thus, siponimod is a promising candidate for repurposing with a favorable cardiac profile.

  • Open Access

    Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation

    by V. S. Krasnov, M. P. Abramova, M. A. Bakalova, A. I. Bezvodinskikh, R. Ts. Bembeeva, Z. S. Gasanova, E. P. Evdoshenko, N. V. Zhukovskaya, O. V. Zaplakhova, S. P. Ivanova, et al.

    Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.

  • Tenecteplase in ischemic stroke in the Russian Federation: first clinical experience beyond the therapeutic window

    by M.S. Cherepianskii, V.V. Dudaite, N.A. Obrosimova, I.N. Evseenko, A.V. Kaneva, A.S. Razdrogova, A.A. Cherepianskaia

    This report presents the successful experience intravenous thrombolysis (IVT) with tenecteplase (Nektelisa, Generium, Russia) for ischemic stroke (IS) therapy at the Regional Vascular Center of the Komi Republican Clinical Hospital. Specifically, it demonstrates the first clinical case in the Russian Federation of successful tenecteplase use for wake-up stroke (WUS) based on DWI/FLAIR mismatch criteria on MRI. Current clinical guidelines support IVT with alteplase for WUS based on MRI DWI/FLAIR mismatch. However, global data on tenecteplase application using these criteria are limited, and such cases have not been previously described In Russia. We present a successful IVT with tenecteplase in a patient with severe ischemic stroke (NIHSS –18) 8.5 hours after the time last known well. Following a single bolus administration, a significant regression of neurological symptoms was observed within the first hour; the NIHSS score decreased to 7 points 10 hours post-thrombolysis. A control CT scan at 24 hours ruled out intracranial hemorrhage, and no therapy-related complications were recorded. At discharge on day 15 (NIHSS –4), the modified Rankin Scale (mRS) score=3, indicating a significant regression of functional deficit. This case demonstrates that tenecteplase administration for wake-up stroke beyond the 4.5-hour window, based on DWI/FLAIR mismatch criteria, is safe and effective. This first successful experience with tenecteplase in the Russian Federation provides an important basis for the implementation of the Nektelisa into clinical practice, including for patient categories with an extended therapeutic window, provided strict adherence to proven selection criteria is maintained.

  • Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

    by N A Shamalov, M Yu Martynov, E I Gusev, N A Marskaya, D R Khasanova, E B Yarovaya, Zh Yu Chefranova, I A Voznuk, A M Alasheev, S E Chuprina, et al.

    Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.


  • Open Access

    Administration of siponimod in real clinical practice in Russia

    by M. V. Davydovskaia, N. Sh. Arzumanyan, E. A. Dubchenko, V. B. Sosina, M. V. Shumilina, E. V. Krivomlina, L. Yu. Gorshkova, M. V. Sutormin, A. A. Sokolova, K. Z. Bakhtiyarova, et al.

    Introduction. The study was driven by the prevalence of secondary progressive multiple sclerosis (SPMS) in Russia and the lack of data on siponimod in the real clinical practice (RCP).Aim. To collect and analyze data on the administration of siponimod in SPMS patients within Russia’s RCP as part of the EMBOSSES study (rEtrospective Multicenter oBservatiOnal Study Siponimod rEal-world Spms).Materials and methods. The study encompassed data of 606 SPMS patients from 11 centers who received siponimod for at least 6 months. The analysed data included demographic and clinical characteristics of patients, changes in the Expanded Disability Status Scale (EDSS) scores over time, percentage of patients with 6-month confirmed disability progression (6mCDP), annualized relapse rate (ARR) for MS, radiological signs of the disease activity and adverse events (AEs).Results. Among the study patients, women predominated (64.9%), while men accounted for 35.1%. The median age of patients was 49.5 (±8.9) years. 143 (23.6%) patients reported relapses during 2 years, whereas relapse-free SPMS was observed in 463 (76.4%) patients. The average EDSS scores remained stable, demonstrating minimal changes from 5.44 (±0.998) to 5.58 (±1.028) scores during the 2-year therapy. The percentage of patients free from 6mCDP was 85.5%. The KaplanMeier analysis revealed that 25% of patients achieved 6mCDP by Month 27 of therapy. The average ARR decreased from 0.14 to 0.032 at 12 months and remained low (0.062) after 2 years of treatment. The MRI showed a decrease in the percentage of patients with Gd+ T1 lesions to their complete absence over 2 years of therapy. Main AEs: lymphopenia, bradycardia, and elevated liver enzymes; serious AEs were observed in 3.3% of all cases.Conclusions. Siponimod demonstrated efficacy in controlling disability progression and inflammatory activity, as well as a favourable safety profile in patients with SPMS in the RCP setting. The results confirm the feasibility of using siponimod in patients with SPMS.


  • Open Access

    Thrombolytic therapy with Revelisa in ischemic stroke: results of the PRIMA international multicenter observational study

    by N. A. Shamalov, D. R. Khasanova, S. V. Marchenko, M. A. Soldatov, T. P Alekseeva, O. V. Androfagina, L. N. Antipova, L. I. Anishchenko, E. M. Beketova, A. A. Bulanov, et al.

    Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (pConclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.


  • Open Access

    The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series

    by E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko

    In recent years, the incidence of multiple sclerosis (MS) has increased in the pediatric population. As there are no separate clinical guidelines for the treatment of pediatric MS and therapeutic options have expanded, it is important to discuss and establish new protocols for the treatment of MS in children and adolescents. This article presents a series of clinical cases of the use of ofatumumab in patients under 18 years of age with a relapsing-remitting MS (RRMS).In the first observation, a 16-year-old female patient with RRMS was switched to ofatumumab therapy due to persistent clinical and radiological activity of the disease during dimethyl fumarate therapy. After the first injection, hyperthermia of up to 38.6 °C and cephalgia were observed, which resolved on the background of symptomatic therapy. No adverse events occurred with subsequent injections, and the patient had clinical and radiological remission during the six-month use of the drug.In the second observation, a 17-year-old female patient with a four-year history of the disease showed resistance to first-line therapy (interferon β1a and glatiramer acetate), so therapy was switched to ofatumumab. After the first injection, persistent hyperthermia of up to 39.3 °C was observed for two days, therefore, premedication with antipyretic and antihistamine medication was performed for the next two injections. No further adverse events were recorded, the therapy was well tolerated, and premedication was not required. The clinical remission of the disease lasted for six months and the results of the control MRI showed no signs of disease activity.In the third observation, ofatumumab therapy was initiated in a 17-year-old patient with rapidly progressive MS. No adverse events were recorded during the 9-month treatment, no signs of the disease activity were detected on the control MRI, and a decrease in the size of some foci was observed. Thus, high short-term efficacy, good tolerability and safety of ofatumumab in the treatment of MS in patients under 18 years of age were demonstrated, which are consistent with the results of the use of the drug in the adult population; no unexpected adverse events were observed. The subcutaneous route of administration contributed to improved patients’ adherence to therapy.


  • Open Access

    Inclisiran in patients with acute ischemic stroke: first data

    by M. S. Cherepianskii, G. M. Ponomareva, I. B. Skiba, R. M. Abakarov, V. V. Dudayte, A. A. Cherepianskaia

    Aim. To evaluate the effect of inclisiran therapy on parameters of lipid metabolism in hospitalized patients with acute ischemic stroke. Material and methods. A prospective, observational, non-randomized study was performed. The study included 12 patients with acute ischemic stroke prescribed with a combination lipid-lowering therapy with inclisiran (284 mg as a single dose). At 15 days after the start of therapy, changes in blood lipid composition were assessed. For quantitative variables, median, maximum and minimum values were determined. The significance of differences between related samples in quantitative variables was assessed using the Mann-Whitney test. Results. Before the start of combination lipid-lowering therapy, total cholesterol (TC) was 7.33 mmol/l and low-density lipoprotein C (LDL-C) was 5.23 mmol/l. At 15 days after the start of inclisiran therapy, TC significantly decreased by 52.1 % and LDL-C decreased by 71.1 %. The proportion of patients who reached the LDL-C goal was 66.7 %. There were no adverse events considered by the investigators to be related with the therapy. Conclusion. The strategy of early administration of inclisiran (or its combination with a statin) in patients with ischemic stroke allows safe achievement of a significant reduction in LDL-C already in 15 days after the start of therapy.


  • Implementation of a program for prevention of cardiovascular diseases and cardiovascular complications in high-risk followed-up patients in constituent entities of the Russian Federation

    by M.V. Sura, N.N. Vezikova, M.G. Glezer, A.A. Efremushkina, I.A. Zolotovskaya, V.V. Ivanenko, S.A. Makarov, A.A. Nekrasov, E.S. Timoshchenko, E.V. Filippov, et al.

    Программа профилактики сердечно-сосудистых заболеваний (ССЗ) у пациентов высокого риска — важнейшая составляющая федерального проекта «Борьба с сердечно-сосудистыми заболеваниями», направленная на достижение целей и результатов его выполнения, включая такой показатель, как снижение смертности от болезней системы кровообращения до 555 случаев на 100 тыс. населения к 2024 г. ЦЕЛЬ ИССЛЕДОВАНИЯ Провести анализ текущего состояния реализации Программы профилактики ССЗ как составной части федерального проекта «Борьба с сердечно-сосудистыми заболеваниями» и соответствующих региональных программ в отдельных субъектах Российской Федерации и предложить направления ее совершенствования. МАТЕРИАЛ И МЕТОДЫ Разработана анкета, включающая 30 вопросов, которые затрагивают основные параметры реализации профилактики ССЗ в субъектах Российской Федерации. Проведено анкетирование и последующее структурированное интервью с экспертами (главными внештатными специалистами — кардиологами, неврологами или терапевтами) 9 субъектов Российской Федерации (Республика Карелия, Республика Коми, Волгоградская область, Алтайский край, Кемеровская область, Самарская область, Нижегородская область, Рязанская область, Московская область). РЕЗУЛЬТАТЫ Программа профилактики ССЗ реализуется в выбранных для исследования субъектах Российской Федерации с марта—июня 2020 г. за счет субсидий федерального бюджета и небольшой доли региональных бюджетов (не более 20%), с 2021 г. пациенты обеспечиваются лекарственными препаратами в течение 2 лет с даты установления диагноза и (или) выполнения хирургического вмешательства. В большей части субъектов Российской Федерации наблюдается рост числа пациентов, включенных в Программу профилактики ССЗ в период с 2020 по 2021 г. Отмечены высокие фактические показатели постановки пациентов, перенесших острое нарушение мозгового кровообращения, инфаркт миокарда, аортокоронарное шунтирование, ангиопластику коронарных артерий со стентированием и катетерную абляцию, на диспансерный учет (минимальный показатель 74,9%) и их обеспечение лекарственными препаратами (минимальный показатель 82,6%) в 2021 г. В некоторых регионах пациенты получают необходимый набор лекарственных препаратов сразу после выписки из стационара. В регионах производятся закупки практически всех лекарственных препаратов в соответствии с перечнем, утвержденным приказом Минздрава России от 24.09.21 №936н «Об утверждении перечня лекарственных препаратов для медицинского применения для обеспечения в амбулаторных условиях лиц, которые перенесли острое нарушение мозгового кровообращения, инфаркт миокарда, а также которым были выполнены аортокоронарное шунтирование, ангиопластика коронарных артерий со стентированием и катетерная абляция по поводу сердечно-сосудистых заболеваний». ЗАКЛЮЧЕНИЕ Среди мер, направленных на повышение эффективности реализации Программы профилактики ССЗ как составной части федерального проекта «Борьба с сердечно-сосудистыми заболеваниями» и соответствующих региональных программ, следует рассматривать создание амбулаторных кардиологических центров, коррекцию лекарственной терапии в зависимости от показаний, обеспечение доступности всех методов диагностики, внедрение электронного рецепта, введение жесткого контроля...